Rosenthal Pavilion 300
Professor, Department of Pediatrics (Pediatric Hematology-Oncology)
Professor, Department of Molecular Pharmacology
Chief, Division of Pediatric Hematology and Oncology
Vice Chairman, Department of Pediatrics
My clinical interests are focused upon the care of children, adolescents and young adults afflicted with sarcomas.
Our laboratory is focused upon osteosarcoma. In the context of this malignancy we study drug resistance, potential therapeutic targets and mechanisms of pathogenesis with the aim being the improved treatment of this disease.
The longstanding focus of the laboratory has been the mechanisms of antifolate resistance that are observed in osteosarcoma. We seek to understand how alterations in membrane transport influence sensitivity versus resistance to antifolates and how normal folate requirements are met in the context of these alterations. We are interested in defining the signal transduction pathways that are relevant to osteosarcoma in part to identify key genes involved in osteosarcoma pathogenesis. It is felt that these signal transduction pathways may be amenable to inhibition by targeted therapies enhancing the standard treatment with cytotoxic chemotherapy. Much of our current efforts are directed towards the IGF signaling pathway. We are interested in understanding the cell of origin of osteosarcoma, which may be a mesenchymal stem cell or a more differentiated osteoblast. We are exploring further, the genetic pathways that drive these cells towards an osteosarcoma phenotype. The laboratory performs preclinical drug studies utilizing osteosarcoma xenografts as a site for the National Cancer Institute funded Pediatric Preclinical Testing Program. A wide variety of functional and molecular approaches are used to study the various candidate genes as well as to address the drug resistance questions.
Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N; on behalf of the COG Bone Tumor Committee. Children's oncology group's 2013 blueprint for research: Bone tumors. Pediatric Blood Cancer 2013; 60:1009-1015
Chou AJ, Gupta R, Bell MD, Riewe KO, Meyers PA, Gorlick R. Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer 2013; 60:580-586.
Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60:1325-1332.
Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, Lor Randall R, Lee S, Kim G, Bernstein M, Gorlick R, Krailo M, Marina N. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. Eur J Cancer 2013; 49:2384-2391.
Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF Jr, Yeager M, Hoover RN, Chanock SJ. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 2013; 45:799-803.
Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (stage 1) of the antibody-maytansinoid conjugate, IMGN901 (lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer Epub Jun 2013.